Kura Oncology, Inc.
KURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Valued at $1.18B, KURA is a small-cap name in its sector. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Market Cap
$1.18B
Beta
0.43
P/E (TTM)
—
P/E (Fwd)
-5.77
EPS (TTM)
$-3.37
EPS (Fwd)
$-2.30
ROE
-167.7%
ROA
-31.3%
Cash
$519.0M
Total Debt
$24.5M
Free CF
-$165.9M
52W Change
61.6%
Annual Financials
Cash vs Debt
Where KURA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KURA finished 36.42% above its 150-day moving average ($9.61) and 33.91% above its 200-day moving average ($9.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KURA overbought or oversold?
At the September 3, 2026 close, KURA's RSI(14) was 72.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kura Oncology, Inc. holds $519.0M in cash against $24.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$165.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -167.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.43 suggests KURA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, KURA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing KURA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.